<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046483</url>
  </required_header>
  <id_info>
    <org_study_id>DISTEMI-Study-01</org_study_id>
    <nct_id>NCT05046483</nct_id>
  </id_info>
  <brief_title>Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI</brief_title>
  <acronym>DISTEMI</acronym>
  <official_title>Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes Mellitus After New Onset of ST-Elevation Myocardial Infarction (STEMI) (DISTEMI Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the prospective observational DISTEMI-Study in patients with and without Diabetes&#xD;
      mellitus after new onset of ST-Elevation Myocardial Infarction (STEMI) aged 18-80 years at&#xD;
      inclusion into the study is to characterize in detail the clinical, metabolical,&#xD;
      immunological and vascular phenotype, investigate the interplay beween myocardial remodelling&#xD;
      and the metabolic phenotype, monitor the progression of the disease and compare the phenotype&#xD;
      of STEMI patients with diabetes mellitus to glucose tolerant patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In detail, the following questions will be answered:&#xD;
&#xD;
        1. Do distinct metabolic phenotypes (with respect to insulin secretion, insulin&#xD;
           sensitivity, circulating free fatty acids and ectopic lipid storage, especially in the&#xD;
           liver) determine myocardial infarct size and decline of contractile function of the&#xD;
           remote myocardium?&#xD;
&#xD;
        2. Which factors modify the progression of the disease (insulin resistance, ectopic lipid&#xD;
           storage, subclinical inflammation, abnormal energy metabolism)? Patients are thoroughly&#xD;
           examined at baseline and one year after STEMI.&#xD;
&#xD;
        3. Can we identify risk profiles and their relevance for development of diabetes-associated&#xD;
           complications as well as long-term progression of diabetes?&#xD;
&#xD;
        4. Can we improve risk assessment algorithms for targeted therapy in line with Precision&#xD;
           Medicine?&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of cardiac function</measure>
    <time_frame>One year</time_frame>
    <description>Measurement of left-ventricular ejection fraction by cardiac magnetic resonance imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of insulin sensitivity (M-Value)</measure>
    <time_frame>One year</time_frame>
    <description>Measurement of whole body insulin sensitivity with hyperinsulinemic euglycemic clamp (HEC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of insulin secretion</measure>
    <time_frame>One year</time_frame>
    <description>Measurement of beta-cell function with oral and intravenous glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of ectopic lipid content</measure>
    <time_frame>One year</time_frame>
    <description>Measurement of cardiac and hepatic lipid content by magnetic resonance spectroscopy (MRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of liver stiffness</measure>
    <time_frame>One year</time_frame>
    <description>Measurement of liver stiffness by transient elastography (Fibroscan®) and magnetic resonance elastography (MRE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of further cardiovascular diseases (CVD) and any diabetes-associated complication</measure>
    <time_frame>One year</time_frame>
    <description>Determination of the prevalence of cardiovascular diseases and diabetes-associated complications</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Diabetes Cohort</arm_group_label>
    <description>Prospectively followed cohort of patients with new onset of ST-elevation myocardial infarction and diabetes mellitus type 1 or type 2 according to criteria of the German Diabetes Society (DDG) (HbA1c ≥ 6.5 % or orale glucose tolerance test), aged 18-80 years at inclusion into the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Glucose Tolerance (NGT) Cohort</arm_group_label>
    <description>Prospectively followed cohort of patients with new onset of ST-elevation myocardial infarction and normal glucose tolerance (HbA1c &lt; 5.9 % and normal oral glucose tolerance test), aged 18-80 years at inclusion into the study</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole-blood, PBMC, serum, plasma, urine, stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Maximum care hospital: Department of Cardiology, Pumonology and Vascular Medicine at&#xD;
        University Hospital Düsseldorf (UKD), Heinrich Heine University (HHU), Düsseldorf.&#xD;
&#xD;
        STEMI patients are recruited by screening at the German Diabetes Center (GDC/DDZ),&#xD;
        Institute for Clinical Diabetology, Leibniz Institute for Diabetes Research at HHU&#xD;
        Düsseldorf.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Condition after new onset of ST-elevation myocardial infarction (STEMI)&#xD;
&#xD;
          -  Age 18-80 years&#xD;
&#xD;
          -  HbA1c &lt; 9.0 %&#xD;
&#xD;
          -  Patients with diagnosis of diabetes mellitus according to DDG criteria (i.e. HbA1c ≥&#xD;
             6.5 % or oral glucose tolerance test)&#xD;
&#xD;
          -  Alternatively: Healthy patients with normal glucose tolerance according to DDG&#xD;
             criteria (i.e. HbA1c &lt; 5.9 % and normal OGTT)&#xD;
&#xD;
          -  Patients capable of giving consent, hemodynamically stable, without sedation (e.g.&#xD;
             opiates) or other interfering medication (e.g. catecholamines)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus category 3 A-H (ADA criteria)&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Infective diseases / fever&#xD;
&#xD;
          -  Immunsuppressive therapy&#xD;
&#xD;
          -  Severe chronic renal, liver or heart disease (e.g. Creatinin ≥ 1.6 mg/dl, peripheral&#xD;
             arterial disease stage 4)&#xD;
&#xD;
          -  Malignant cancer&#xD;
&#xD;
          -  Severe chronic psychiatric illness or addiction&#xD;
&#xD;
          -  Participation in an intervention trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Diabetes Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Roden, Prof.</last_name>
    <phone>+49-211-3382-0</phone>
    <phone_ext>201</phone_ext>
    <email>michael.roden@ddz.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clara Möser, MD</last_name>
    <phone>+49-211-3382-0</phone>
    <phone_ext>318</phone_ext>
    <email>clara.moeser@ddz.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>German Diabetes Center</name>
      <address>
        <city>Düsseldorf</city>
        <state>North-Rhine Westphalia</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Study Center</last_name>
      <phone>+49-211-3382-0</phone>
      <phone_ext>209</phone_ext>
      <email>studienzentrum@ddz.de</email>
    </contact>
    <investigator>
      <last_name>Michael Roden, Prof., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Szendrödi, Prof., MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oana-Patricia Zaharia, Dr., MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clara Möser, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Diabetes Center</investigator_affiliation>
    <investigator_full_name>julia szendrödi</investigator_full_name>
    <investigator_title>Prof. Dr. Julia Szendrödi</investigator_title>
  </responsible_party>
  <keyword>ST-elevation myocardial infarction</keyword>
  <keyword>STEMI</keyword>
  <keyword>Cardiovascular diseases</keyword>
  <keyword>CVD</keyword>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Normal glucose tolerance</keyword>
  <keyword>Non-alcoholic fatty liver disease</keyword>
  <keyword>NAFLD</keyword>
  <keyword>Liver fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

